Keenova Therapeutics Reports Q2 2026 Financial Results

What Happened Keenova Therapeutics plc announced its quarterly financial results in an 8-K filed on August 11, 2026. The filing states the Company reported its financial results for the three months ended June 30, 2026; the detailed second-quarter results are included as Exhibit 99.1 to the filing. The report was signed by Christiana Stamoulis, President and Chief Financial Officer.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (Q2 2026 results).
• Period covered: three months ended June 30, 2026; filing date: August 11, 2026.
• Exhibit included: Exhibit 99.1 — Second Quarter Financial Results (detailed numbers are in the exhibit).
• Report signed by: Christiana Stamoulis, President and CFO, on behalf of Keenova Therapeutics plc.

Why It Matters This 8-K notifies investors that Keenova has released its quarterly earnings information; the full financial details (revenue, net income/loss, cash position, and any operational metrics or guidance) are contained in Exhibit 99.1. Retail investors should review the attached exhibit or the company’s press release to see specific figures and assess implications for revenue trends, profitability, liquidity, or any updated business outlook.